Targets › UL51
1 program from 1 company in 22 trials: 12 Phase 2, 6 Phase 1, 3 Phase 4, 1 Phase 3; Genitourinary, Immunology, Infectious disease; next expected readout Nov 2026.
Open in Phaseline: the race on UL51, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| University of Pennsylvania | 2-[18F]-FA Voltage-gated calcium channel modulator | CHRNA4, OPRK1, OPRD1, OPRM1, UL51, ADRA2A, ADRA2C, ADRA2B, Ion channels, CACNB4, CACNB2, CACNB1, CACNB3, TNF, SLC6A4, HTR2A, HTR2C, FKBP1A, CD86, CD80, PDE4A, PDE4D, PDE4B, PDE4C, PDE3A, CHRNB2, STN | Phase 4 | Alcohol Use Disorder; Acute Kidney Injury; Insomnia; Giant Cell Arteritis … | Nov 2026 |
Alcohol Use Disorder (2) Head and Neck Squamous Cell Carcinoma (2) Acute Kidney Injury (1) Insomnia (1) Giant Cell Arteritis (1) Opiate Withdrawal Syndrome (1) Ketoses, Metabolic (1) Cytomegalovirus Infections (1) Alcohol Use Disorder (AUD) (1) Relapsed/Refractory Multiple Myeloma (1) Castleman Disease (1) Relapsing Polychondritis (1)
small molecule (1)
University of Pennsylvania (1)
CHRNA4 (1) OPRK1 (1) OPRD1 (1) OPRM1 (1) ADRA2A (1) ADRA2C (1) ADRA2B (1) Ion channels (1) CACNB4 (1) CACNB2 (1) CACNB1 (1) CACNB3 (1)
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.